Aktuellt
SENASTE
Redeye is encouraged by the positive results from Orexo’s clinical phase I trial with the company’s nasal epinephrine (adrenaline), OX640, demonstrating proof-of-concept and bioavailability. We will return with a revised update on the case wherein we will review OX640 in more detail.
LÄS MER
